Anti-Fibrinolytic Drugs - Taiwan | Statista Market Forecast

The projected revenue for the Anti-Fibrinolytic Drugs market in Taiwan is expected to reach US$62.46m in 2024.
Furthermore, it is anticipated that the revenue will experience a compound annual growth rate (CAGR 2024-2029) of 4.60%, leading to a market volume of US$78.21m by 2029.
When compared globally, it is noteworthy that United States will generate the highest revenue, amounting to US$9.86bn in 2024.
Taiwan's pharmaceutical market for anti-fibrinolytic drugs is witnessing a steady growth due to increasing demand for advanced medical treatments.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

Taiwan is a country that is known for its advanced medical facilities and healthcare system. The Anti-Fibrinolytic Drugs market in Taiwan has been growing steadily over the years, driven by various factors such as customer preferences, local special circumstances, and underlying macroeconomic factors.

Customer preferences: Customers in Taiwan have been increasingly demanding Anti-Fibrinolytic Drugs due to the rise in medical conditions that require such drugs. The aging population in Taiwan has been a significant factor in the growth of the Anti-Fibrinolytic Drugs market as the elderly are more susceptible to medical conditions that require these drugs. Additionally, the increasing awareness of the benefits of Anti-Fibrinolytic Drugs has also contributed to the growth of the market.

Trends in the market: The Anti-Fibrinolytic Drugs market in Taiwan has been experiencing a shift towards more advanced and innovative drugs. The market has been witnessing the introduction of new drugs that are more effective and have fewer side effects. Additionally, there has been a trend towards the development of personalized medicine, which has led to the creation of drugs that are tailored to individual patients' needs.

Local special circumstances: Taiwan has a robust healthcare system that provides universal healthcare coverage to its citizens. The government has been actively promoting the use of generic drugs to reduce healthcare costs. This has led to the growth of the generic Anti-Fibrinolytic Drugs market in Taiwan as they are more affordable than branded drugs. Additionally, the government has been investing in research and development to promote the growth of the pharmaceutical industry, which has led to the development of new Anti-Fibrinolytic Drugs.

Underlying macroeconomic factors: Taiwan has a stable economy with a high GDP per capita. The country has been experiencing steady economic growth, which has led to an increase in healthcare spending. Additionally, the government has been investing heavily in the healthcare sector, which has led to the growth of the Anti-Fibrinolytic Drugs market. The country's strategic location has also made it an attractive destination for pharmaceutical companies to invest in, which has led to the growth of the Anti-Fibrinolytic Drugs market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.